Healthc Inform Res.  2022 Apr;28(2):176-180. 10.4258/hir.2022.28.2.176.

Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation

• Nguyen VL
• Ahn S
• Hoa PQ
• Long NP
• Ahn S
• Cho YS
• Shin JG

• KMID: 2529800
• DOI: http://doi.org/10.4258/hir.2022.28.2.176

Figure

• 

  Figure 1 The cloud-based architecture of the cPMTb Smart R&D Workstation (Center for Personalized Precision Medicine of Tuberculosis: Smart Research and Development Workstation). CRA: clinical research associate, CRC: clinical research coordinator.

• 

  Figure 2 Overview of functions of the cPMTb Smart R&D Workstation (Center for Personalized Precision Medicine of Tuberculosis: Smart Research and Development Workstation). (A) Clinical case review screen for an individual patient. (B) Interactive scatter plots of drug concentrations with various options for filtering and normalization.

• 

  Figure 3 Bi-directional flow of information in the cPMTb Smart R&D Workstation (Center for Personalized Precision Medicine of Tuberculosis: Smart Research and Development Workstation) for personalized medicine of anti-tuberculosis drugs. CDSS: clinical decision support system, PK/PD: pharmacokinetics/pharmacodynamics, IVIVE: in vivo–in vitro extrapolation, PGx: pharmacogenomics, ADME: absorption, distribution, metabolism, and elimination, PBPK/PD: physiology-based pharmacokinetics/pharmacodynamics.

Reference

References

1. World Health Organization. Global Tuberculosis Report [Internet]. Geneva, Switzerland: World Health Organization;2020. [cited at 2022 Apr 10]. Available from: https://www.who.int/teams/global-tuberculosis-programme/data .

2. Korea Disease Control and Prevention Agency. Annual report on the notified tuberculosis in Korea, 2019. Cheongju, Korea: Korea Disease Control and Prevention Agency;2020.

3. Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr. Management of drug-resistant tuberculosis. Lancet. 2019; 394(10202):953–66.

4. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019; 393 (10181):1642–56.

5. Lee Y, Raviglione MC, Flahault A. Use of digital technology to enhance tuberculosis control: scoping review. J Med Internet Res. 2020; 22(2):e15727.

6. Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal. 2015; 102:9–16.

7. Cremers S, Guha N, Shine B. Therapeutic drug monitoring in the era of precision medicine: opportunities! Br J Clin Pharmacol. 2016; 82(4):900–2.

8. Parvez MM, Jung JA, Shin HJ, Kim DH, Shin JG. Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake. Antimicrob Agents Chemother. 2016; 60(5):3096–105.

9. Sun Q, Liu HP, Zheng RJ, Wang P, Liu ZB, Sha W, et al. Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case-control study. Clin Drug Investig. 2017; 37(12):1125–36.

10. Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, et al. Isoniazid population pharmacokinetics and dose recommendation for Korean patients with tuberculosis based on target attainment analysis. J Clin Pharmacol. 2021; 61(12):1567–78.

11. Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, et al. Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. Int J Infect Dis. 2022; 117:8–14.